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The metabolic fate of dietary n-3 docosapentaenoic acid (DPA) in mammals is currently unknown. The aim of the present study was to deter-
mine the extent of conversion of dietary DPA to DHA and EPA in rats. Four groups of male weanling Sprague–Dawley rats (aged 5 weeks)
were given 50 mg of DPA, EPA, DHA or oleic acid, daily for 7 d by gavage. At the end of the treatment period, the tissues were analysed for
concentrations of long-chain PUFA. DPA supplementation led to significant increases in DPA concentration in all tissues, with largest increase
being in adipose (5-fold) and smallest increase being in brain (1·1-fold). DPA supplementation significantly increased the concentration
of DHA in liver and the concentration of EPA in liver, heart and skeletal muscle, presumably by the process of retroconversion. EPA sup-
plementation significantly increased the concentration of EPA and DPA in liver, heart and skeletal muscle and the DHA concentration in liver.
DHA supplementation elevated the DHA levels in all tissues and EPA levels in the liver. Adipose was the main tissue site for accumulation
of DPA, EPA and DHA. These data suggest that dietary DPA can be converted to DHA in the liver, in a short-term study, and that in
addition it is partly retroconverted to EPA in liver, adipose, heart and skeletal muscle. Future studies should examine the physiological
effect of DPA in tissues such as liver and heart.
DHA: Docosapentaenoic acid: EPA: n-3 PUFA
The interest in n-3 PUFA developed rapidly after two Nobel
Prize winning discoveries of particular PG, metabolites of ara-
chidonic acid (AA), by Vane & Samuelsson(1) in the late
1960s and early 1970s. Since then there have been many
studies suggesting the beneficial effects of n-3 fatty acids in
reducing risk of cardiovascular events, diabetes, inhibiting
growth of tumour cells, modulating gene expression and
anti-inflammatory activity(2 – 7). The parent n-3 PUFA is
a-linolenic acid (ALA; 18 : 3n-3), which is found in high
concentration in some plant oils. In mammals, some of the
ingested ALA is metabolised to long-chain n-3 PUFA
(LCPn-3), namely EPA (20 : 5n-3), docosapentaenoic acid
(DPA; 22 : 5n-3) and DHA (22 : 6n-3) by a series of desatura-
tions and elongations (see Fig. 1). This metabolic processing
of ALA to DHA is inefficient(8), and much of the ingested
ALA is either deposited in tissue adipose stores as ALA or
catabolised by mitochondrial b-oxidation to yield energy
(ATP) and CO2
(9). Many studies have reported that feeding
relatively high levels of ALA in either animals or human sub-
jects leads to increased DPA levels, but not DHA levels,
suggesting the steps between DPA and DHA are rate-limiting
steps in this metabolic pathway(10,11). In contrast, ingested
DHA is rapidly and efficiently deposited in brain, liver and
other tissues(12). There is not much literature available on
the fate of DPA. Two cell culture studies have looked at
the effect of DPA supplementation in endothelial cells and
hepatocytes, respectively, and reported that DPA supplemen-
tation increases both DPA and EPA levels but not DHA in
these cells(13,14). However, no animal studies have been con-
ducted to investigate the conversion of pure DPA to DHA in
mammals, presumably because DPA has only recently
become available for in vivo studies (in milligram amounts).
DPA is found in common foods like fish, fish oil, lean red
meat and n-3-enriched eggs(15); therefore, it is important to
understand the metabolic fate of DPA. In the present
paper, we report the effect of DPA supplementation on
DPA, EPA and DHA concentrations in rat tissues. The
hypothesis being tested was that dietary supplementation
of DPA will increase both tissue DHA and EPA levels.
The novelty of the present study is that it focuses on the
metabolism of DPA in a rodent model, which has not been
investigated before.
*Corresponding author: Professor Andrew J. Sinclair, fax þ61 3 9251 7282, email andrew.sinclair@deakin.edu.au
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Materials and methods
Animals and diets
Thirty-two 4-week-old male weanling Sprague–Dawley rats
were randomly divided into four groups of eight animals.
The rats were maintained on an ad libitum normal chow diet
with water throughout the study. The total lipid content of
the chow diet used was 5·7 (g/100 g of wet weight) and the
three main unsaturated fatty acids present in the chow diet
were oleic acid (29·7 %), linoleic acid (31·2 %) and ALA
(3·4 %); EPA, DPA and DHA were not detected. The rats
were pair housed and allowed 1 week to acclimatise. The
rats were then administered 50 mg of DPA, EPA, DHA or
oleic acid (Nu-Chek Prep, Inc., Elysian, MN, USA) by daily
oral gavaging for 7 d. The dose and duration used in the pre-
sent study were based on evidence from previously published
studies that have successfully used doses of 90–100 mg/d of
PUFA, for rats weighing up to 140–220 g. These studies
demonstrated that changes in fatty acid composition of long-
chain PUFA occurred within 3 d of supplementation(16 – 19).
In the present study, we used 50 mg of fatty acids for animals
weighing 68–101 g. Thus, it was expected that the dose of
50 mg of fatty acids given for 7 d would be sufficient to
detect changes in tissue fatty acid composition.
The weight of the animals was recorded every day and on
the 8th day the animals were sacrificed by lethal injection of
Lethobarb (Virbac, Peakhurst, NSW, Australia). Brain, heart,
epididymal fat (adipose), skeletal muscle and liver were removed
from the animals, washed in ice-cold saline (0·9 % NaCl solution)
and then dried on paper towel. After weighing, the tissues were
wrapped in foil and stored at 2808C for fatty acid analysis.
Lipid analysis
The tissues were minced and the tissue lipids were extracted by
chloroform–methanol, 2:1 as described by Sinclair et al. (20). An
aliquot of the total lipids from each tissue, plus an internal
standard of docosatrienoic acid (22 : 3; Nu-Chek Prep, Inc.),
was reacted with 2 % H2SO4 in methanol for 3 h at 808C to
form the fatty acid methyl esters; they were passed through a
silica Sep-Pak to remove cholesterol and then the fatty acid
methyl esters were separated by capillary GLC using a
50 m £ 0·32 mm (inner diameter) fused silica-bonded phase
column (BPX70, SGE, Melbourne, Vic, Australia). The
column oven was programmed to rise after 3 min at
125–2208C at 88C/min with a He gas flow rate of 43 cm/s as
the carrier gas. Fatty acids were identified by comparison with
standard mixtures of fatty acid methyl esters and the results
were calculated using response factors derived from chromato-
graphing standards of known composition (Nu-Chek Prep, Inc.).
Statistical analysis
Data analysis was performed using SPSS version 15.0 for
Windows (SPSS, Inc., Chicago, IL, USA). Significant differences
between dietary groups were tested using a one-way ANOVA for
each type of fatty acid for both fatty acid analysis and gene
expression. Post hoc comparisons were made using the least
significant difference test with a significance level of 0·05.
Ethics approval
All experimental procedures involving animals were performed
under the ‘Australian code of practice for the care and use of ani-
mals for scientific purposes’ and were approved by La Trobe
University Animal Ethics Committee (AEC07-53-P) and
Deakin University Animal Welfare Committee (AEX 23/2008).
Results
Body and tissue weights
There was no significant difference in the body weights of ani-
mals between various dietary groups at the start and the end of
the study. The mean (^SD) body weights of rats at the start
and end of study were 75·9 (SD 5·8) and 122·4 (SD 17·4) g,
respectively. There were no significant differences in the
tissue weights between treatments.
Tissue fatty acid concentrations
Adipose tissue contained the highest concentration of each of
the three LCP with amounts ranging from 30 to 57 mg/g tissue
Fig. 1. Pathway for metabolism of a-linolenic acid (ALA) to long-chain n-3
PUFA. In mammals, some of the ingested ALA is metabolised to long-chain
n-3 fatty acids by a series of elongations and desaturations. The figure
shows the enzymes involved in this pathway. DPA, docosapentaenoic acid.
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compared with values of less than 3 mg/g in other tissues
(Table 1). In liver, muscle and brain tissue, the concentration
of DHA was between 1 and 3 mg/g; for DPA, the concen-
tration ranged from 0·1 to 2 mg/g, while for EPA the range
was from 0·02 to 0·4 mg/g tissue. The rats supplemented
with DHA showed a significant increase in tissue DHA
content in all the five tissues studied. The largest proportional
increase in DHA occurred in adipose (3·4-fold) and skeletal
muscle (2·4-fold) and the least change was in brain
(1·1-fold). It was also observed that DHA supplementation
led to a significant increase in EPA concentration in liver.
DPA supplementation resulted in statistically significant
accumulation of DPA in all tissues analysed except adipose
tissue. DPA supplementation also led to a significant increase
in EPA concentrations in liver, heart and skeletal muscle and
a non-significant increase in adipose tissue. Interestingly,
DPA supplementation also led to a significant increase in
DHA concentration in liver.
Supplementation with EPA led to a significant increase
in tissue EPA and DPA concentrations in liver, heart and
skeletal muscle and a non-significant increase in adipose tissue.
EPA supplementation also increased DHA concentrations sign-
ificantly in liver. All three n-3 PUFA led to a significant
decrease in AA concentrations in liver and heart (Figs. 2 and 3).
Discussion
The aim of the present study was to examine the effect of
DPA supplementation on LCPn-3 proportions in the tissues
of animals fed 50 mg of n-3 fatty acids per day for 7 d.
It was observed that the primary site of DPA deposition was
adipose followed by heart, liver and skeletal muscle. Adipose
was also the main site for deposition of fed EPA and DHA in
the present study. Fu & Sinclair(10) reported that major sites
of EPA and DPA deposition, in guinea pigs fed with diets
containing 17·3 % ALA (of total diet lipid) for 4 weeks,
were adipose, skin and carcass.
It was observed that DPA supplementation increased DPA
concentration in liver, heart, skeletal muscle and brain. It was
also observed that DPA supplementation led to a significant
increase in EPA concentrations in liver, heart and skeletal
muscle and a non-significant increase in EPA concentrations
in adipose tissue suggesting the retroconversion of DPA into
EPA in vivo. The process of retroconversion was first
described by Stoffel et al. (21) for DHA, and subsequent
work by Christensen et al. (22,23) in human fibroblasts indi-
cated the retroconversion of both DHA and DPA was likely
to involve the peroxisomal acyl-CoA oxidase. Retroconver-
sion of DPA into EPA has also been reported in endothelial
cells, fetal skin fibroblasts and hepatocytes(13,14,24). The
extent of ‘apparent’ retroconversion of DPA to EPA
(DEPA £ 100/D(DPA þ EPA)) was 28 % in liver, 19 %
in adipose tissue, 12 % in skeletal muscle, 4 % in heart and
negligible in brain.
It was also observed from the present study that EPA-fed
animals showed a significant increase in EPA and DPA con-
centrations in the liver, heart and skeletal muscle. These
data confirm the findings of previously published cell culture
studies, which showed that EPA is converted into DPA in
endothelial and liver cells(13,14). It is evident from the present
study that EPA and DPA are interconverted in the body and
therefore DPA may act as a source of EPA in the body and
vice versa. This is particularly relevant in adipose tissue
that had the highest concentrations of these PUFA and conse-
quently adipose may act as a reservoir of these fatty acids.
Supplementation with EPA had no effect on brain EPA
Table 1. Tissue fatty acid concentrations in brain, adipose and skeletal muscle of animals in various dietary
groups*
(Mean values and standard deviations)
OA control EPA group DPA group DHA group
Fatty acids Mean SD Mean SD Mean SD Mean SD
Brain
OA 2·97a 0·03 3·03a,b 0·05 3·12b 0·05 3·10a,b 0·06
AA 2·01a 0·05 2·01a 0·04 2·03a 0·03 1·98a 0·05
EPA 0·02a 0·00 0·02a 0·00 0·02a 0·00 0·03a 0·00
DPA 0·08a 0·01 0·10b 0·01 0·11b 0·01 0·07a 0·00
DHA 2·50a 0·05 2·62a,b 0·03 2·65a,b 0·06 2·70b 0·08
Adipose
OA 948·33a 64·66 1031·55a 119·07 823·57a,b 62·55 703·85b 50·27
AA 40·48a 4·64 36·28a 5·79 31·88 a 2·95 29·28a 3·73
EPA 3·87a 0·50 30·42a 7·95 14·37a 4·32 5·29a 0·90
DPA 11·00a 2·48 29·96a 9·07 55·68a 13·73 23·48a 5·43
DHA 16·62a 1·20 23·20a,b 3·16 27·01a,b 3·03 57·04a 10·23
Skeletal muscle
OA 3·98a 0·68 3·95a 0·62 3·35a 0·48 3·62a 0·45
AA 1·48a 0·08 1·26 a 0·03 1·23a 0·03 1·22a 0·02
EPA 0·03a 0·00 0·23b 0·04 0·11b,c 0·01 0·04a,c 0·01
DPA 0·27a 0·27 0·50b 0·03 0·87c 0·06 0·21a 0·02
DHA 0·55a 0·04 0·66b 0·03 0·61a,b 0·02 1·31c 0·05
OA, oleic acid; AA, arachidonic acid; DPA, docosapentaenoic acid.
a,b,c Mean values within a row with unlike superscript letters were significantly different (P,0·05).
* Fatty acid composition of various tissues from rats supplemented with 50 mg of OA, EPA, DPA or DHA for 7 d. Results are
expressed as mg/g of tissue (n 8). Data were analysed using one-way ANOVA and post hoc comparisons were made using
the least significant difference test.
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levels that are known to be very low (in the present study
0·02 mg/g). It has recently been suggested that low levels of
EPA in brain phospholipids compared with DHA may be
the result of its rapid b-oxidation upon uptake by the brain(25).
Another very significant finding of the present study was
that supplementation of rats with DPA led to a significant
increase in liver DHA concentrations and a non-significant
increase in brain, compared with the control group-fed oleic
acid. The DPA-fed group showed a 60 % increase in liver
DHA compared with the group-fed DHA. Liver is regarded
as a major site for PUFA synthesis(9) and since this was a
short-term study only, there may have been insufficient time
for the increased liver DHA to be delivered to the other tissues
via plasma lipoprotein transport. The two previously published
cell culture studies that have looked at DPA supplementation
failed to demonstrate an increase in tissue DHA levels. It is not
clear whether this was due to a limited ability of these
particular cells to desaturate PUFA or to competition between
24 : 5n-3 and ALA for metabolism to DHA(26).
In the present study, the DHA-fed group was regarded as a
control group to judge the effectiveness of increases in DHA
concentration in the EPA- and DPA-fed groups. There was
an increase in the tissue DHA concentrations in the DHA-
fed group with the largest rise occurring in adipose tissue
(3·4-fold), followed by skeletal muscle (2·4-fold), heart
(2·1-fold), liver (1·76-fold) and brain (1·1-fold). It was no sur-
prise that significant increases in DHA were observed as this
has been observed by many groups in a variety of dietary
supplementation studies(26 – 28). It was also observed that
DHA supplementation increased the EPA levels in liver
suggesting retroconversion into EPA.
In the present study, DPA, EPA and DHA supplementation
also led to a significant decrease in tissue AA levels in
liver and heart and a non-significant decrease in muscle
and adipose. This could be explained by the fact that
LCPn-3 are known to have an inhibitory effect on D6- and
5-desaturases(29,30), which are involved in synthesis of AA
from linoleic acid. Also supplementation of cells with
Fig. 2. Fatty acid composition of liver tissue of rats supplemented with 50 mg oleic acid (OA), EPA, docosapentaenoic acid (DPA) or DHA for 7 d. (a) OA concen-
tration in liver tissue; (b) arachidonic acid (AA) concentration in liver tissue; (c) EPA concentration in liver tissue; (d) DPA concentration in liver tissue; (e) DHA
concentration in liver tissue. Results are expressed as mg/g of tissue (n 8). Values are means, with standard deviations represented by vertical bars. Data were
analysed using one-way ANOVA and post hoc comparisons were made using the least significant difference test. a,b,c Mean values with unlike letters were
significantly different (P , 0·05).
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the LCPn-3 could have led to competition for the enzyme
acyl-CoA transferase thereby decreasing the incorporation of
AA into phospholipids(31).
To our knowledge, so far there have been very few studies
that have investigated the biochemical effects of DPA. We
expect this might be due to the relatively limited availability
and high cost of pure DPA. But in light of the present litera-
ture, it can be speculated that the physiological consequences
of accumulation of DPA in tissues may be related to accumu-
lation of DPA, EPA and DHA from DPA and to inhibition of
AA metabolism. Two studies are worth mentioning since both
reported an effect of pure DPA on platelet function through
AA pathway inhibition(32,33). One study reported that platelets
metabolise 22 : 5n-3 into 11- and l4-hydroxy DPA via an indo-
methacin-insensitive pathway(32). They also reported that
when DPA was released along with AA in platelets, it
inhibited cyclo-oxygenase enzyme thereby reducing the
thromboxane B2 and 5,8,10-heptadecatrienoic acid production
from AA. Akiba et al. (33) looked at the effects of DPA on
platelet aggregation and AA metabolism in rabbit platelets
and compared them with those of EPA and DHA. The results
showed that n-3 fatty acids inhibited collagen- or AA-stimulated
platelet aggregation dose dependently, and that DPA was the
most potent inhibitor. These results suggest that DPA possesses
potent activity for interfering with the cyclo-oxygenase pathway
and accelerating the lipoxygenase pathway.
In conclusion, the data presented in the present study
demonstrated that oral consumption of dietary DPA in
young male rats increased the concentration of DHA in
liver but not other tissues. Furthermore, DPA was partially
retroconverted to EPA in liver, muscle, adipose and
heart. Future studies should investigate the physiological and
biochemical effects of DPA ingestion compared with that
of EPA and DHA.
Acknowledgements
The present research was funded by Meat and Livestock
Australia (Project code: D.MHN.0022) and by cluster funds
from Faculty of Health, Medicine, Nursing and Behavioural
Fig. 3. Fatty acid composition of heart tissue of rats supplemented with 50 mg oleic acid (OA), EPA, docosapentaenoic acid (DPA) or DHA for 7 d. (a) OA concen-
tration in heart tissue; (b) arachidonic acid (AA) concentration in heart tissue; (c) EPA concentration in heart tissue; (d) DPA concentration in heart tissue; (e) DHA
concentration in heart tissue. Results are expressed as mg/g of tissue (n 8). Values are means, with standard deviations represented by vertical bars. Data were
analysed using one-way ANOVA and post hoc comparisons were made using the least significant difference test. a,b,c Mean values with unlike letters were
significantly different (P , 0·05).
G. Kaur et al.36
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
Sciences, Deakin University. There is no conflict of interest of
any personal, financial or academic nature, among the authors.
Contribution of authors. G. K. and A. J. S. designed the study.
D. P. B. coordinated and carried out the animal procedures
with G. K. D. B. performed the fatty acid analysis. G. K.
performed the statistical analysis and wrote the manuscript.
A. J. S., M. G., D. C.-S. and D. P. B. along with G. K.
contributed to the final version of the manuscript.
References
1. Raju TN (1999) The Nobel Chronicles: 1982: Sune Karl
Bergstrom (b 1916); Bengt Ingemar Samuelsson (b 1934);
John Robert Vane (b 1927). Lancet 354, 1914.
2. Arita M, Yoshida M, Hong S, et al. (2005) Resolvin E1, an
endogenous lipid mediator derived from omega-3 eicosapentaenoic
acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced
colitis. Proc Natl Acad Sci U S A 102, 7671–7676.
3. Aktas H & Halperin JA (2004) Translational regulation of gene
expression by omega-3 fatty acids. J Nutr 134, 2487S–2491S.
4. Tsuji M, Murota SI & Morita I (2003) Docosapentaenoic acid
(22 : 5, n-3) suppressed tube-forming activity in endothelial cells
induced by vascular endothelial growth factor. Prostaglandins
Leukot Essent Fatty Acids 68, 337–342.
5. Kitajka K, Puskas LG, Zvara A, et al. (2002) The role of n-3
polyunsaturated fatty acids in brain: modulation of rat brain
gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci
U S A 99, 2619–2624.
6. Fujikawa M, Yamazaki K, Hamazaki T, et al. (1994) Effect of
eicosapentaenoic acid ethyl ester on albuminuria in streptozoto-
cin-induced diabetic rats. J Nutr Sci Vitaminol (Tokyo) 40,
49–61.
7. Shimizu H, Ohtani K, Tanaka Y, et al. (1995) Long-term effect
of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of
non-insulin dependent diabetic patients. Diabetes Res Clin
Pract 28, 35–40.
8. Brenna JT, Salem N Jr, Sinclair AJ, et al. (2009) alpha-
Linolenic acid supplementation and conversion to n-3 long-
chain polyunsaturated fatty acids in humans. Prostaglandins
Leukot Essent Fatty Acids 80, 85–91.
9. Sinclair AJ, Attar-Bashi NM & Li D (2002) What is the role of
alpha-linolenic acid for mammals? Lipids 37, 1113–1123.
10. Fu Z & Sinclair AJ (2000) Increased alpha-linolenic acid
intake increases tissue alpha-linolenic acid content and apparent
oxidation with little effect on tissue docosahexaenoic acid in the
guinea pig. Lipids 35, 395–400.
11. Attar-Bashi NM, Li D & Sinclair AJ (2003) Does
conjugated linoleic acid increase conversion of a-linolenic
acid to docosahexaenoic acid in humans? Asia Pac J Clin
Nutr 12, Suppl. S44.
12. Sinclair AJ (1975) Incorporation of radioactive polyunsaturated
fatty acids into liver and brain of developing rat. Lipids 10,
175–184.
13. Pawar A & Jump DB (2003) Unsaturated fatty acid regulation
of peroxisome proliferator-activated receptor alpha activity in
rat primary hepatocytes. J Biol Chem 278, 35931–35939.
14. Benistant C, Achard F, Ben Slama S, et al. (1996) Docosapen-
taenoic acid (22 : 5, n-3): metabolism and effect on prostacyclin
production in endothelial cells. Prostaglandins Leukot Essent
Fatty Acids 55, 287–292.
15. Mann NJ, Johnson LG, Warrick GE, et al. (1995) The arachido-
nic acid content of the Australian diet is lower than previously
estimated. J Nutr 125, 2528–2535.
16. Mann NJ, Warrick GE, O’Dea K, et al. (1994) The effect of
linoleic, arachidonic and eicosapentaenoic acid supplementation
on prostacyclin production in rats. Lipids 29, 157–162.
17. Williams MA, Tinoco J, Yang YT, et al. (1989) Feeding
pure docosahexaenoate or arachidonate decreases plasma tri-
acylglycerol secretion in rats. Lipids 24, 753–758.
18. Sanigorski AJ, Sinclair AJ & Hamazaki T (1996) Platelet and
aorta arachidonic and eicosapentaenoic acid levels and in vitro
eicosanoid production in rats fed high-fat diets. Lipids 31,
729–735.
19. Huang YS, Mitchell J, Jenkins K, et al. (1984) Effect of dietary
depletion and repletion of linoleic acid on renal fatty acid com-
position and urinary prostaglandin excretion. Prostaglandins
Leukot Med 15, 223–228.
20. Sinclair AJ, O’Dea K, Dunstan G, et al. (1987) Effects on
plasma lipids and fatty acid composition of very low fat diets
enriched with fish or kangaroo meat. Lipids 22, 523–529.
21. Stoffel W, Eker, Assad H, et al. (1970) Enzymatic studies on
the mechanism of the retroconversion of C22-polyenoic fatty
acids to their C20-homologues. Hoppe Seylers Z Physiol
Chem 351, 1545–1554.
22. Christensen E, Woldseth B, Hagve TA, et al. (1993) Peroxiso-
mal beta-oxidation of polyunsaturated long chain fatty acids
in human fibroblasts. The polyunsaturated and the saturated
long chain fatty acids are retroconverted by the same acyl-
CoA oxidase. Scand J Clin Lab Invest Suppl 215, 61–74.
23. Reddy JK & Hashimoto T (2001) Peroxisomal beta-oxidation
and peroxisome proliferator-activated receptor alpha: an adap-
tive metabolic system. Annu Rev Nutr 21, 193–230.
24. Rosenthal MD, Garcia MC, Jones MR, et al. (1991) Retro-
conversion and delta 4 desaturation of docosatetraenoate
(22 : 4(n-6)) and docosapentaenoate (22 : 5(n-3)) by human
cells in culture. Biochim Biophys Acta 1083, 29–36.
25. Chen CT, Liu Z, Ouellet M, et al. (2009) Rapid beta-oxidation
of eicosapentaenoic acid in mouse brain: an in situ study. Pros-
taglandins Leukot Essent Fatty Acids 80, 157–163.
26. Portolesi R, Powell BC & Gibson RA (2007) Competition
between 24 : 5n-3 and ALA for Delta 6 desaturase may limit
the accumulation of DHA in HepG2 cell membranes. J Lipid
Res 48, 1592–1598.
27. Ward GR, Huang YS, Xing HC, et al. (1999) Effects of gamma-
linolenic acid and docosahexaenoic acid in formulae on brain
fatty acid composition in artificially reared rats. Lipids 34,
1057–1063.
28. Nasrollahzadeh J, Siassi F, Doosti M, et al. (2008) The influence
of feeding linoleic, gamma-linolenic and docosahexaenoic acid
rich oils on rat brain tumor fatty acids composition and fatty
acid binding protein 7 mRNA expression. Lipids Health Dis 7, 45.
29. Garg ML, Sebokova E, Thomson AB, et al. (1988) Delta
6-desaturase activity in liver microsomes of rats fed diets
enriched with cholesterol and/or omega 3 fatty acids. Biochem
J 249, 351–356.
30. Cho HP, Nakamura M & Clarke SD (1999) Cloning, expression,
and fatty acid regulation of the human delta-5 desaturase. J Biol
Chem 274, 37335–37339.
31. Lands WE, Libelt B, Morris A, et al. (1992) Maintenance of
lower proportions of (n-6) eicosanoid precursors in phospholi-
pids of human plasma in response to added dietary (n-3) fatty
acids. Biochim Biophys Acta 1180, 147–162.
32. Careaga MM & Sprecher H (1984) Synthesis of two hydroxy
fatty acids from 7,10,13,16,19-docosapentaenoic acid by
human platelets. J Biol Chem 259, 14413–14417.
33. Akiba S, Murata T, Kitatani K, et al. (2000) Involvement of
lipoxygenase pathway in docosapentaenoic acid-induced inhi-
bition of platelet aggregation. Biol Pharm Bull 23, 1293–1297.
Metabolism of docosapentaenoic acid (22 : 5n-3) 37
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
